BOSQF:OTC-Better Plant Sciences Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 0.09

Change

0.00 (0.00)%

Market Cap

USD 9.34M

Volume

3.29M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

Better Plant Sciences Inc (BOSQF) Stock Analysis:
Based on the Better Plant Sciences Inc stock forecasts from 0 analysts, the average analyst target price for Better Plant Sciences Inc is not available over the next 12 months. Better Plant Sciences Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Better Plant Sciences Inc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Better Plant Sciences Inc’s stock price was USD 0.09. Better Plant Sciences Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Better Plant Sciences Inc
No recent average analyst rating found for Better Plant Sciences Inc

About

Better Plant Sciences Inc., through its subsidiaries, develops, markets, and sells of plant-based products for health and wellness. The company offers cosmetic and therapeutic products made of cannabis sativa hemp root oil and essential oils. It also develop and acquire intellect ...Read More

Company Website : http://betterplantsciences.com

Address : 1238 Homer Street, Vancouver, BC, Canada, V6B 2Y5

Employees : 19

Fiscal Year End : November

Currency: USD

Country : USA

Technical Indicators

Beta : 1.80

200 Day Moving Average : 0.08

50 Day Moving Average : 0.12

Shares Held By Insiders : 19.27%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

+0.45 (+1.36%)

 USD72.20B 22.76 13.89
MKGAF MERCK Kommanditgesellschaft au..

+4.00 (+2.41%)

 USD72.00B 22.44 13.89
TKPHF Takeda Pharmaceutical Company ..

+0.31 (+1.10%)

 USD44.09B 13.07 0.06
SGIOF Shionogi & Co. Ltd

+0.05 (+0.09%)

 USD16.01B 21.15 0.11
SGIOY Shionogi & Co. Ltd

+0.01 (+0.11%)

 USD16.01B 21.17 0.11
SFOSF Shanghai Fosun Pharmaceutical ..

-0.15 (-3.33%)

 USD15.75B 17.30 2.67
ESALF Eisai Co. Ltd

N/A

 USD12.67B 27.89 0.10
ESALY Eisai Co. Ltd

-0.44 (-1.01%)

 USD12.09B 27.39 0.10
GNHAF Vifor Pharma AG

N/A

 USD11.36B 77.87 17.10
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

 USD10.43B 79.00 0.21

ETFs Containing BOSQF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -19.01% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.01% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.72% N/A N/A N/A N/A
Risk Adjusted Return -49.10% N/A N/A N/A N/A
Market Capitalization 9.34M N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.46 N/A N/A N/A N/A
Price / Cash Flow Ratio -0.78 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -1,068.95% N/A N/A N/A N/A
Return on Assets -122.30% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.80 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.